Malignant tumor of pancreas (disorder)

Clinical Trial: SPARC

Year Started: 2015

A phase 1 trial of pre-operative, margin intensive, stereotactic body radiation therapy for pancreatic cancer



Access:
Access restricted at present
Type:
Clinical Trial
Status:
In progress
Consent restrictions:
No restrictions


Associated Data Type Procurement Timeframe
Followup records 0 - 3 months
Imaging data 0 - 3 months
Pathology records 0 - 3 months
Physiological/biochemical measurements 0 - 3 months
Treatment records 0 - 3 months


Male

Adult (> 40 years)

11 - 100 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
Whole blood -60°C to -85°C N/A Not applicable 0 - 10%


Female

Adult (> 40 years)

11 - 100 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
Whole blood -60°C to -85°C N/A Not applicable 0 - 10%


Male

Adult (> 40 years)

11 - 100 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
Peripheral blood mononuclear cells (PBMC) -60°C to -85°C N/A Not applicable 0 - 10%


Female

Adult (> 40 years)

11 - 100 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
Peripheral blood mononuclear cells (PBMC) -60°C to -85°C N/A Not applicable 0 - 10%


Male

Adult (> 40 years)

11 - 100 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
Plasma -60°C to -85°C N/A Not applicable 0 - 10%


Female

Adult (> 40 years)

11 - 100 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
Plasma -60°C to -85°C N/A Not applicable 0 - 10%

Local recurrence of malignant tumor of pancreas (disorder)

Clinical Trial: SCALOP-2

Year Started: 2017

T-SCALOP is the translational sample collection associated with the SCALOP-2 trial. The SCALOP2 trial is a randomised phase II/III study with a 2x2 factorial design plus an additional chemotherapy control arm in patients with locally advanced non-metastatic pancreatic cancer. Patients whose disease remains stable after treatment with gemcitabine and abraxane will be randomised to one of five arms, consisting of capecitabine in combination with radiotherapy, with and without inclusion of the Phospho-AKT inhibitor nelfinavir, and a chemotherapy control arm receiving gemcitabine and abraxane alone. The study aims to recruit 262 patients over a period of 48 months from 40 UK centres. T-SCALOP aims to establish a collection of samples focusing on developing blood-borne biomarkers for tumour detection and response prediction. In addition to residual tumour tissue from diagnostic biopsy, research blood will be collected from patients at trial entry, start of chemoradiotherapy, 4-6 weeks after chemoradiotherapy and at progression. The samples will be used to compare tumour DNA with circulating cell-free plasma DNA to determine whether blood borne biomarkers can be used as a surrogate for primary tumour. They will also help determine whether alteration in the levels of specific somatic events correlate with benefit of a given intervention. The collection will also help to evaluate plasma biomarkers related to hypoxia before and during nelfinivir treatment and correlate with clinical outcome. The sample collection has been held in the Wales Cancer Bank since 2022. For sample enquiries, please contact WCB directly.



Access:
Access restricted at present
Type:
Clinical Trial
Status:
Completed
Consent restrictions:
No restrictions


Associated Data Type Procurement Timeframe
Clinical records > 6 months
Followup records > 6 months
Pathology records > 6 months


Female

Adult (> 40 years)

101 - 500 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
Plasma -60°C to -85°C N/A Not applicable 51 - 75%


Male

Adult (> 40 years)

101 - 500 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
Plasma -60°C to -85°C N/A Not applicable 51 - 75%


Male

Adult (> 40 years)

1 - 10 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
Serum -60°C to -85°C N/A Not applicable 0 - 10%


Female

Adult (> 40 years)

101 - 500 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
Serum -60°C to -85°C N/A Not applicable 51 - 75%


Male

Adult (> 40 years)

101 - 500 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
Tissue specimen Surgical procedure (procedure) RT Paraffin Not applicable 51 - 75%


Female

Adult (> 40 years)

101 - 500 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
Tissue specimen Surgical procedure (procedure) RT Paraffin Not applicable 51 - 75%

Local recurrence of malignant tumor of esophagus (disorder)

Clinical trial: Cytofloc

Year Started: 2018

Evaluation of a Non-Endoscopic Immunocytological Device (Cytosponge™) for post chemo-radiotherapy surveillance in patients with oesophageal cancer – a feasibility study



Access:
Closed to access
Type:
Clinical Trial
Status:
Completed
Consent restrictions:
No restrictions


Associated Data Type Procurement Timeframe
Followup records 0 - 3 months
Pathology records 0 - 3 months
Physiological/biochemical measurements 0 - 3 months
Survey data 0 - 3 months
Treatment records 0 - 3 months


Female

Young adult (18 - 40 years)

1 - 10 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
Tissue specimen Biopsy (procedure) RT N/A Not applicable 0 - 10%
Plasma -60°C to -85°C N/A Not applicable 0 - 10%


Male

Adult (> 40 years)

1 - 10 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
Tissue specimen Biopsy (procedure) RT N/A Not applicable 0 - 10%
Plasma -60°C to -85°C N/A Not applicable 0 - 10%


Female

Adult (> 40 years)

1 - 10 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
Tissue specimen Biopsy (procedure) RT N/A Not applicable 0 - 10%
Plasma -60°C to -85°C N/A Not applicable 0 - 10%


Male

Young adult (18 - 40 years)

1 - 10 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
Tissue specimen Biopsy (procedure) RT N/A Not applicable 0 - 10%
Plasma -60°C to -85°C N/A Not applicable 0 - 10%

Barrett's esophagus (disorder)

Clinical Trial: AspECT

Year Started: 2005

AspECT: A Phase III, Randomised Study of Aspirin and Esomeprazole Chemoprevention in Barrett's Metaplasia. Trial has 10-year follow up period with samples collected throughout. Patient age groups given in the Sample Sets are the age of the patients at trial randomisation



Access:
Open to applicants
Type:
Clinical Trial
Status:
Completed
Consent restrictions:
Commercial restriction, DNA restriction


Associated Data Type Procurement Timeframe
Followup records 0 - 3 months
Pathology records 3 - 6 months
Physiological/biochemical measurements 0 - 3 months
Treatment records 0 - 3 months


Male

Adult (> 40 years)

1001 - 3000 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
Tissue specimen Surgical procedure (procedure) RT Paraffin Affected 51 - 75%
Whole blood -60°C to -85°C N/A Not applicable 51 - 75%


Male

Young adult (18 - 40 years)

101 - 500 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
Tissue specimen Surgical procedure (procedure) RT Paraffin Affected 51 - 75%
Whole blood -60°C to -85°C N/A Not applicable 51 - 75%


Female

Adult (> 40 years)

101 - 500 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
Tissue specimen Surgical procedure (procedure) RT Paraffin Affected 51 - 75%
Whole blood -60°C to -85°C N/A Not applicable 51 - 75%


Female

Young adult (18 - 40 years)

11 - 100 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
Tissue specimen Surgical procedure (procedure) RT Paraffin Affected 51 - 75%
Whole blood -60°C to -85°C N/A Not applicable 51 - 75%

Malignant tumor of ovary (disorder)

Clinical Trial: 6MP

Year Started: 2011

See clinicaltrials.gov record NCT01432145 for more information about the study. Whole blood and plasma samples collected pre and post treatment in approx 70 participants and associated FFPE tumour tissue for approx 25 participants. Study data also available on request.



Access:
Open to applicants
Type:
Disease specific
Status:
Completed
Consent restrictions:
No restrictions


Associated Data Type Procurement Timeframe
There is no associated data for this collection.


Female

Adult (> 40 years)

11 - 100 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
Plasma -60°C to -85°C N/A Not applicable 0 - 10%
Tissue specimen Surgical procedure (procedure) RT N/A Not applicable 0 - 10%
Whole blood -60°C to -85°C N/A Not applicable 0 - 10%

Malignant tumor of ovary (disorder)

Clinical Trial: OCTOVA

Year Started: 2017

See ClinicalTrials.gov reference NCT03117933 for more information about the study. Whole blood and plasma samples pre and post-treatment with i.PARPi ii. control or iii. PARPi & anti-angiogenic. FFPE diagnostoc tumour sample.



Access:
Access restricted at present
Type:
Disease specific
Status:
In progress
Consent restrictions:
No restrictions


Associated Data Type Procurement Timeframe
There is no associated data for this collection.


Female

Adult (> 40 years)

11 - 100 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
Plasma -60°C to -85°C N/A Not applicable 0 - 10%
Tissue specimen Surgical procedure (procedure) RT N/A Affected 0 - 10%
Whole blood -60°C to -85°C N/A Not applicable 0 - 10%

Malignant tumor of lung (disorder)

Clinical Trial: ARCADIAN

Year Started: 2021

A phase I dose escalation study to investigate combining the antimalarial drug atovaquone with chemoradiotherapy in non-small cell lung cancer, using a time to event continual reassessment method (TiTE CRM).



Access:
Access restricted at present
Type:
Clinical Trial
Status:
In progress
Consent restrictions:
No restrictions


Associated Data Type Procurement Timeframe
Biomarker datasets > 6 months
Followup records > 6 months
Imaging data > 6 months
Physiological/biochemical measurements > 6 months
Treatment records > 6 months


Female

Adult (> 40 years)

1 - 10 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
Plasma -60°C to -85°C Not applicable 75% -99%


Male

Adult (> 40 years)

1 - 10 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
Plasma -60°C to -85°C Not applicable 75% -99%


Female

Adult (> 40 years)

1 - 10 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
Tissue specimen RT Paraffin Not applicable 75% -99%


Male

Adult (> 40 years)

1 - 10 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
Tissue specimen RT Paraffin Not applicable 75% -99%

Malignant tumor of rectum (disorder)

Clinical Trial: CEDAR

Year Started: 2019

A Phase 1 trial of the safety, tolerability and biological effects of intravenous Enadenotucirev, a novel oncolytic virus, in combination with chemoradiotherapy in locally advanced rectal cancer



Access:
Access restricted at present
Type:
Clinical Trial
Status:
In progress
Consent restrictions:
No restrictions


Associated Data Type Procurement Timeframe
There is no associated data for this collection.


Female

Young adult (18 - 40 years)

1 - 10 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
Faeces RT Not applicable 0 - 10%
RNA -60°C to -85°C Not applicable 0 - 10%
Tissue specimen RT Paraffin Not applicable 0 - 10%
Whole blood RT Not applicable 0 - 10%


Female

Adult (> 40 years)

1 - 10 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
Faeces RT Not applicable 0 - 10%
RNA -60°C to -85°C Not applicable 0 - 10%
Tissue specimen RT Paraffin Not applicable 0 - 10%
Whole blood RT Not applicable 0 - 10%


Male

Young adult (18 - 40 years)

1 - 10 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
RNA -60°C to -85°C Not applicable 0 - 10%
Tissue specimen RT Not applicable 0 - 10%
Whole blood RT Not applicable 0 - 10%
Faeces RT Not applicable 0 - 10%


Male

Adult (> 40 years)

1 - 10 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Macroscopic Assessment % of Sample Set
Faeces RT Not applicable 0 - 10%
RNA -60°C to -85°C Not applicable 0 - 10%
Tissue specimen RT Not applicable 0 - 10%
Whole blood RT Not applicable 0 - 10%